Clinical significance of enhancer of zeste homolog 2 expression in colorectal cancer cases

K. Mimori, K. Ogawa, M. Okamoto, T. Sudo, H. Inoue, M. Mori

研究成果: ジャーナルへの寄稿学術誌査読

65 被引用数 (Scopus)

抄録

Introduction. Enhancer of zeste homolog 2 (EZH-2) is a polycomb group (PcG) protein, and the clinical significance of this protein has not yet been determined in colorectal cancer (CRC) cases. Recently, investigations of CRC cases have focused on the interaction between EZH-2 and histone deacetylase-1 (HDAC-1). Patients and methods. We performed real time RT-PCR to evaluate the expression of EZH-2 mRNA quantitatively in tumour and normal tissue samples from 61 cases of CRC. The expression of HDAC-1 in CRC cases was also examined in order to compare its levels with those of EZH-2. Results. Among the CRC cases, 32 patients whose tumour tissue showed overexpression of EZH-2 also had a significantly worse prognosis than did 29 patients whose tumour tissue showed low EZH-2 expression (p<0.05). In addition, a significant correlation between EZH-2 and HDAC-1 expression was observed in 61 CRC cases (p<0.05). Moreover, 20 cases of both high EZH-2 and high HDAC-1 expression showed poor prognoses than did 19 cases in which there was low EZH-2 and low HDAC-1 expression (p<0.05). Conclusion. The abundant expression of EZH-2 in CRC cases indicated that EZH-2 may be an oncogene and a prognostic marker for CRC cases. We discovered there was concordant expression of HDAC-1 with EZH-2 in clinical CRC cases, in addition to the fact that higher expression levels of both genes predicted a poor prognosis.

本文言語英語
ページ(範囲)376-380
ページ数5
ジャーナルEuropean Journal of Surgical Oncology
31
4
DOI
出版ステータス出版済み - 5月 2005

!!!All Science Journal Classification (ASJC) codes

  • 外科
  • 腫瘍学

フィンガープリント

「Clinical significance of enhancer of zeste homolog 2 expression in colorectal cancer cases」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル